Business Context and Reporting Period
This Form 8-K Current Report was filed by Aligos Therapeutics, Inc. on November 16, 2021. The filing addresses corporate governance changes, specifically the expansion of the Board of Directors and the appointment of a new director.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on personnel and governance matters.
Material Changes
- Board Expansion: The Board of Directors increased the number of authorized directors from seven to eight.
- New Appointment: Bridget Martell, M.D., was appointed as a Class III director effective November 16, 2021. Her term expires at the 2023 annual meeting of stockholders.
- Compensation Arrangements: Dr. Martell will receive a $35,000 annual retainer (prorated for the remainder of 2021) and an initial stock option grant to purchase 30,000 shares of Common Stock under the 2020 Incentive Award Plan.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on business strategy, or discussion of risks and contingencies. It is a procedural report regarding director appointment and compensation.
Key Facts for Investor Verification
- Verify the total number of authorized directors is now eight.
- Confirm Dr. Bridget Martell's term expiration date is the 2023 annual meeting.
- Note the specific compensation package: $35,000 annual retainer and 30,000 stock options.
- Review the referenced non-employee director compensation program (Exhibit 10.11 to Form S-1) for full terms.